NCT07504679|Not Yet Recruiting
Adipose Visceral and Epicardial Risk Evaluation
AVERE
Loading search results
AVERE
Sponsor study identifier
interventional
400
0 countries
N/A
Study Start
May 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
March 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this procedure-based interventional study without drugs or devices is to investigate the molecular mechanisms underlying metabolically unfavorable obesity and related clinical phenotypes, in order to identify non-invasive biomarkers capable of early prediction of metabolic syndrome, type 2 diabetes mellitus, MASLD, and cardiovascular disease in adult participants without known cardiovascular or liver disease. The main questions it aims to answer are:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 26, 2026
Actual (reported)April 1, 2026
Actual (reported)May 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Association between epicardial and visceral fat thickness and low-grade inflammatory biomarkers with cardiometabolic and hepatic outcomes
Evaluation of the relationship between epicardial and visceral adipose tissue thickness and plasma levels of low-grade inflammatory biomarkers (hs-CRP, IL-6, TNF-α) with the presence of: * Subclinical atherosclerotic disease; * Metabolic syndrome * Type 2 diabetes mellitus * Metabolic dysfunction-associated steatotic liver disease (MASLD)
Single time point at enrollment (baseline)
Demographic data, anthropometric measures, physical examination and information about medical history, concomitant medication and variables related to inclusion criteria are collected. Peripheral venous blood sampling for collection of biological specimens to perform biochemical, cellular, and molecular analyses aimed at assessing immuno-metabolic and inflammatory parameters.
Collection of blood specimens for biochemical, cellular, and molecular studies.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
First Submitted
March 26, 2026
First Posted
April 1, 2026
Study Start
May 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
Ventricular Tachyarrhythmia (VT) Storm, Gene Expression in Implantable Cardioverter Defibrillator (ICD) Patients With Electrical Storm
Selective Coronary Vein Sampling in Left Bundle Branch Block and CRT
Contact the study team to confirm eligibility.
March 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
April 1, 2026
Record last verified: 2026-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: